To determine if cardiovascular risk indices including postprandial hypertriglyceridaemia are modified favourably by nicotinic acid (niacin) in patients with polycystic ovary syndrome (PCOS): a randomised double blind placebo controlled parallel study

Trial Profile

To determine if cardiovascular risk indices including postprandial hypertriglyceridaemia are modified favourably by nicotinic acid (niacin) in patients with polycystic ovary syndrome (PCOS): a randomised double blind placebo controlled parallel study

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Oct 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 11 May 2010 'Merck and Co.' added as trial sponsor as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top